Prostate Cancer Liquid Biopsy Biomarkers' Clinical Utility in Diagnosis and Prognosis

被引:47
作者
Matuszczak, Milena [1 ]
Schalken, Jack A. [2 ]
Salagierski, Maciej [1 ]
机构
[1] Univ Zielona Gora, Coll Med, Dept Urol, PL-65046 Zielona Gora, Poland
[2] Radboud Univ Nijmegen, Med Ctr, Dept Urol, NL-6525 GA Nijmegen, Netherlands
关键词
cancer biomarkers; prostate cancer; liquid biopsy; prognosis; diagnosis; early detection; ANTIGEN; 3; PCA3; HEALTH INDEX; URINARY PCA3; SIGNIFICANTLY IMPROVES; 4-KALLIKREIN PANEL; EPIGENETIC ASSAY; ISOFORM P2PSA; MEN; RISK; PREDICT;
D O I
10.3390/cancers13133373
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary In prostate cancer, overdiagnosis and overtreatment is a common problem for clinicians. Accurate diagnosis and prognosis are essential to avoid unnecessary biopsy and to increases the effectiveness of treatment. A new, easy-to-use and non-invasive test based on liquid biopsy biomarkers such as Progensa PCA3, MyProstateScore, ExoDx, SelectMDx, PHI, 4K, Stockholm3 and ConfirmMDx have been developed to improve diagnosis, prognosis and to help guide the decision-making process. This article provides an overview of the above-mentioned commercial tests. The performance and financial aspects of the tests have been compared using available studies. Then the application of biomarker tests as an adjunct to multiparametric MRI in the diagnosis, prognosis and monitoring of prostate cancer has been discussed. Prostate cancer (PCa) is the most common cancer in men worldwide. The current gold standard for diagnosing PCa relies on a transrectal ultrasound-guided systematic core needle biopsy indicated after detection changes in a digital rectal examination (DRE) and elevated prostate-specific antigen (PSA) level in the blood serum. PSA is a marker produced by prostate cells, not just cancer cells. Therefore, an elevated PSA level may be associated with other symptoms such as benign prostatic hyperplasia or inflammation of the prostate gland. Due to this marker's low specificity, a common problem is overdiagnosis, which leads to unnecessary biopsies and overtreatment. This is associated with various treatment complications (such as bleeding or infection) and generates unnecessary costs. Therefore, there is no doubt that the improvement of the current procedure by applying effective, sensitive and specific markers is an urgent need. Several non-invasive, cost-effective, high-accuracy liquid biopsy diagnostic biomarkers such as Progensa PCA3, MyProstateScore ExoDx, SelectMDx, PHI, 4K, Stockholm3 and ConfirmMDx have been developed in recent years. This article compares current knowledge about them and their potential application in clinical practice.
引用
收藏
页数:29
相关论文
共 104 条
[1]   Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients [J].
Alshalalfa, Mohammed ;
Verhaegh, Gerald W. ;
Gibb, Ewan A. ;
Santiago-Jimenez, Maria ;
Erho, Nicholas ;
Jordan, Jennifer ;
Yousefi, Kasra ;
Lam, Lucia L. C. ;
Kolisnik, Tyler ;
Chelissery, Jijumon ;
Seiler, Roland ;
Ross, Ashley E. ;
Karnes, R. Jeffrey ;
Schaeffer, Edward M. ;
Lotan, Tamara T. ;
Den, Robert B. ;
Freedland, Stephen J. ;
Davicioni, Elai ;
Klein, Eric A. ;
Schalken, Jack A. .
ONCOTARGET, 2017, 8 (31) :50804-50813
[2]   PCA3 Molecular Urine Test for Predicting Repeat Prostate Biopsy Outcome in Populations at Risk: Validation in the Placebo Arm of the Dutasteride REDUCE Trial [J].
Aubin, Sheila M. J. ;
Reid, Jennifer ;
Sarno, Mark J. ;
Blase, Amy ;
Aussie, Jacqueline ;
Rittenhouse, Harry ;
Rittmaster, Roger ;
Andriole, Gerald L. ;
Groskopf, Jack .
JOURNAL OF UROLOGY, 2010, 184 (05) :1947-1952
[3]  
Aubry W, 2013, AM HEALTH DRUG BENEF, V6, P15
[4]   Critical Assessment of Preoperative Urinary Prostate Cancer Antigen 3 on the Accuracy of Prostate Cancer Staging [J].
Auprich, Marco ;
Chun, Felix K. -H. ;
Ward, John F. ;
Pummer, Karl ;
Babaian, Richard ;
Augustin, Herbert ;
Luger, Ferdinand ;
Gutschi, Stefan ;
Budaeus, Lars ;
Fisch, Margit ;
Huland, Hartwig ;
Graefen, Markus ;
Haese, Alexander .
EUROPEAN UROLOGY, 2011, 59 (01) :96-105
[5]   Performance of Prostate Health Index in Biopsy Naive Black Men [J].
Babajide, Rilwan ;
Carbunaru, Samuel ;
Nettey, Oluwarotimi S. ;
Watson, Karriem S. ;
Holloway-Beth, Alfreda ;
McDowell, Tiffany ;
Ben Levi, Josef ;
Murray, Marcus ;
Stinson, James ;
Hollowell, Courtney M. P. ;
Dalton, Daniel P. ;
Moore, Le'Andre ;
Kittles, Rick A. ;
Gann, Peter H. ;
Schaeffer, Edward M. ;
Murphy, Adam B. .
JOURNAL OF UROLOGY, 2021, 205 (03) :718-724
[6]   The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years [J].
Boegemann, Martin ;
Stephan, Carsten ;
Cammann, Henning ;
Vincendeau, Sebastien ;
Houlgatte, Alain ;
Jung, Klaus ;
Blanchet, Jean-Sebastien ;
Semjonow, Axel .
BJU INTERNATIONAL, 2016, 117 (01) :72-79
[7]   Prosbiotate: A Multicenter, Prospective Analysis of Infectious Complications after Prostate Biopsy [J].
Bruyere, Franck ;
Malavaud, Sandra ;
Bertrand, Philippe ;
Decock, Aliette ;
Cariou, Gerard ;
Doublet, Jean Dominique ;
Bernard, Louis ;
Bugel, Hubert ;
Conquy, Sophie ;
Sotto, Albert ;
Boiteux, Jean Paul ;
Pogu, Bertrand ;
Rebillard, Xavier ;
Mongiat-Artus, Pierre ;
Coloby, Patrick .
JOURNAL OF UROLOGY, 2015, 193 (01) :145-150
[8]   A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range [J].
Catalona, William J. ;
Partin, Alan W. ;
Sanda, Martin G. ;
Wei, John T. ;
Klee, George G. ;
Bangma, Chris H. ;
Slawin, Kevin M. ;
Marks, Leonard S. ;
Loeb, Stacy ;
Broyles, Dennis L. ;
Shin, Sanghyuk S. ;
Cruz, Amabelle B. ;
Chan, Daniel W. ;
Sokoll, Lori J. ;
Roberts, William L. ;
van Schaik, Ron H. N. ;
Mizrahi, Isaac A. .
JOURNAL OF UROLOGY, 2011, 185 (05) :1650-1655
[9]   Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging [J].
Catalona, WJ ;
Southwick, PC ;
Slawin, KM ;
Partin, AW ;
Brawer, MK ;
Flanigan, RC ;
Patel, A ;
Richie, JP ;
Walsh, PC ;
Scardino, PT ;
Lange, PH ;
Gasior, GH ;
Loveland, KG ;
Bray, KR .
UROLOGY, 2000, 56 (02) :255-260
[10]   Urinary PCA3 as a Predictor of Prostate Cancer in a Cohort of 3,073 Men Undergoing Initial Prostate Biopsy [J].
Chevli, K. Kent ;
Duff, Michael ;
Walter, Peter ;
Yu, Changhong ;
Capuder, Brian ;
Elshafei, Ahmed ;
Malczewski, Stephanie ;
Kattan, Michael W. ;
Jones, J. Stephen .
JOURNAL OF UROLOGY, 2014, 191 (06) :1743-1748